Pantoprazole
Also known as: Pantozol Control · Controloc Control · Somac Control · PANTOPRAZOLE SODIUM
General information only. Anpheros does not diagnose and does not recommend treatment. Talk to a doctor or pharmacist about your situation. In an emergency, call 112 (or your local emergency number).
Codes
- RxNorm
- 40790 pantoprazole
- EMA
- EMEA/H/C/001013, EMEA/H/C/001097, EMEA/H/C/001098
Official indications
Quoted unchanged from official product information, in English. Listed alphabetically by product, not ranked.
EMA (EU) Controloc Control
Short-term treatment of reflux symptoms (e.g. heartburn, acid regurgitation) in adults.
Source: European Medicines Agency (EMA), Controloc Control — EPAR, 25/05/2023. © European Medicines Agency.
Document date: 25/05/2023 · Official document →
FDA (USA) PANTOPRAZOLE SODIUM
1 INDICATIONS AND USAGE Pantoprazole sodium delayed-release tablets are indicated for: Pantoprazole sodium delayed-release tablet is a proton pump inhibitor (PPI) indicated for the following: • Short-Term Treatment of Erosive Esophagitis Associated with Gastroesophageal Reflux Disease (GERD) (1.1) • Maintenance of Healing of Erosive Esophagitis ( 1.2) • Pathological Hypersecretory Conditions Including Zollinger-Ellison (ZE) Syndrome (1.3 ) 1.1 Short-Term Treatment of Erosive Esophagitis Associated With Gastroesophageal Reflux Disease (GERD) Pantoprazole sodium delayed-release tablets are indicated in adults and pediatric patients five years of age and older for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis (EE). For those adult patients who have not healed after 8 weeks of treatment, an additional 8-week course of pantoprazole sodium delayed-release tablets may be considered. Safety of treatment beyond 8 weeks in pediatric patients has not been established. 1.2 Maintenance of Healing of Erosive Esophagitis Pantoprazole sodium delayed-release tablets are indicated for maintenance of healing of EE and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with GERD. Controlled studies did not extend beyond 12 months. 1.3 Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome Pantoprazole sodium delayed-release tablets are indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison (ZE) Syndrome.
Data provided by the U.S. Food and Drug Administration.
Document date: 20260826 · Official document →
EMA (EU) Pantozol Control
Short-term treatment of reflux symptoms (e.g. heartburn, acid regurgitation) in adults.
Source: European Medicines Agency (EMA), Pantozol Control — EPAR, 25/05/2023. © European Medicines Agency.
Document date: 25/05/2023 · Official document →
EMA (EU) Somac Control
Short-term treatment of reflux symptoms (e.g. heartburn, acid regurgitation) in adults.
Source: European Medicines Agency (EMA), Somac Control — EPAR, 24/05/2023. © European Medicines Agency.
Document date: 24/05/2023 · Official document →
Related terms in the cited sources
Has an official indication for
- Acid reflux (GERD) Condition
In alphabetical order.
Other treatments A–Z
What people report
Not enough data yet. Anonymous counts appear here only for groups of at least 20 people who agreed to share them.
External resources
Questions
What is Pantoprazole approved for in the European Union?
Short-term treatment of reflux symptoms (e.g. heartburn, acid regurgitation) in adults. (Source: European Medicines Agency (EMA), Controloc Control — EPAR, 25/05/2023. © European Medicines Agency.)
Sources and attribution
- Source: European Medicines Agency (EMA) — EPAR. © European Medicines Agency.
- Data provided by the U.S. Food and Drug Administration.
- Names other than the official source titles: Anpheros translations and plain-language names, made with AI assistance and checked automatically; the source names are in English.
- This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
- Source: European Medicines Agency (EMA), Controloc Control — EPAR, 25/05/2023. © European Medicines Agency.
- Source: European Medicines Agency (EMA), Pantozol Control — EPAR, 25/05/2023. © European Medicines Agency.
- Source: European Medicines Agency (EMA), Somac Control — EPAR, 24/05/2023. © European Medicines Agency.
Anpheros Search catalog 2026.10.5, published 17 October 2026. About the data →
About this page. This page brings together public information from official sources, each cited where it is used. It is not medical advice, it is not a diagnosis, and it does not tell you which treatment to take.
Treatments. Indications are quoted unchanged from official product information (European Medicines Agency, U.S. Food and Drug Administration). They describe what a medicine is approved for, not whether it is right for you. Approved uses can differ between countries. Always read the package leaflet and follow your doctor's or pharmacist's advice.
What people report. Figures marked "reported by Anpheros users" are anonymous counts from at least 20 people who agreed to share them. They show what people report, not what works, and they are not clinical evidence.
Links between terms. "May be associated with" means the link appears in a cited source. It does not mean you have that condition.
In an emergency, call 112 (or your local emergency number). Do not delay seeking medical help because of something you read here.